The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Improving the outcomes of patients with lenalidomide-refractory myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the challenge of treating patients with lenalidomide-refractory multiple myeloma (MM), highlighting that a subanalysis of the PREAMBLE registry showed that the clinical outcomes for this population remain poor. Dr Cerchione advocates for more dedicated sub-analyses of clinical trial data from this difficult-to-treat patient population to improve outcomes. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In EHA 2025 in Milan, the therapeutic revolution in multiple myeloma is continuing, but unfortunately we have some courses of patients in which the results are not so outstanding. And particularly in this sub-analysis from preamble registry, which I am proud to be the presenting author of, we have seen that lenalidomide refractory patients have in this moment a not so good outcome, particularly considering not only the long-term progression-free survival, but also the potential sequencing after the failure of lenalidomide alone or in lenalidomide-based regimens...
In EHA 2025 in Milan, the therapeutic revolution in multiple myeloma is continuing, but unfortunately we have some courses of patients in which the results are not so outstanding. And particularly in this sub-analysis from preamble registry, which I am proud to be the presenting author of, we have seen that lenalidomide refractory patients have in this moment a not so good outcome, particularly considering not only the long-term progression-free survival, but also the potential sequencing after the failure of lenalidomide alone or in lenalidomide-based regimens. So we have to consider also for potential clinical trials ongoing, in my opinion, some dedicated sub-analysis to lenalidomide refractory patients because in this moment I think that is the most important problem to cover in our real world and I think that also in the brilliant studies that are ongoing with bispecific antibodies, CAR-T and new cellular therapies, this cohort of patients has to be, in my opinion, explored in a particular way because if we want really to eradicate multiple myeloma, if we want to obtain a deep response in all the categories of patients, we have to care also about really difficult to treat populations, and in this moment lenalidomide refractory patients seem to be one of them. If we consider data from this international registry in which there are thousands of patients taken from really important institutions, I think that this is something that we have to cover as soon as possible. If we want to go to the cure of multiple myeloma, that is the best wish that I always give to our patients, to their caregivers and to all myeloma researchers.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
